Last reviewed · How we verify
NCT06231225
Study on the Effect of Incentive Spirometer-based Respiratory Training on the Long COVID-19
NA trial testing Incentive Spirometer respiratory training in COVID-19 Pandemic in 100 participants. Not yet recruiting.
30 June 2025
Quick facts
| Lead sponsor | National Taipei University of Nursing and Health Sciences |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 July 2024 |
| Primary completion | 30 June 2025 |
| Estimated completion | 1 August 2026 |
Drugs / interventions tested
- Incentive Spirometer respiratory training
Conditions studied
- COVID-19 Pandemic — all drugs for COVID-19 Pandemic →
- Diabetes — all drugs for Diabetes →
- Hypertension — all drugs for Hypertension →
- Cardiac Disease — all drugs for Cardiac Disease →
Sponsor
National Taipei University of Nursing and Health Sciences
Who can join
Adults 20 to 90, any sex, with COVID-19 Pandemic or Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The COVID-19 pandemic has emerged as the most significant public health crisis of the 21st century. As of the end of January 2023, global confirmed cases have exceeded 670 million, with a domestic cumulative total of 10.24 million cases, including occurrences of reinfection. Beyond acute symptoms following infection, patients and society face the challenge of long-term complications associated with COVID-19. Termed 'Post COVID-19 condition' or 'Long COVID' by the World Health Organization (WHO), this encompasses symptoms appearing within three months of the initial infection. Symptoms of Long COVID reveal chronic damage inflicted by the virus on multiple organ systems, including fatigue, cognitive impairment, chest tightness, palpitations, difficulty breathing, and depression. Despite continuous efforts by healthcare professionals to find suitable treatments, no medication has been confirmed to effectively prevent or reduce post-COVID-19 sequelae. These health issues impose significant burdens and disturbances on patients' quality of life, economies, and societies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06231225
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Pandemic
Currently open trials in the same condition.
- NCT05825651 — Long COVID and Its Associations With Health Outcomes in Older Adults · active not recruiting
- NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting
- NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting
- NCT06208943 — Neural and Cognitive Consequences of COVID-19 Survival · recruiting
Other National Taipei University of Nursing and Health Sciences trials
Trials by the same sponsor.
- NCT07586696 — Effects of Exercise Board Games on Cognitive Function in Older Adults · NA · active not recruiting
- NCT07243717 — Information-Assisted Intervention for Potential Living Kidney Donors · NA · recruiting
- NCT07302568 — Exercise and Gezaixi Interventions on Community-Dwelling Older Adults · NA · completed
- NCT07196488 — Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses · NA · recruiting
- NCT07086261 — Using SRT to Improve The Drinking Problem Behavior of Elderly People With Dementia During The Care of Day Care · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06231225 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taipei University of Nursing and Health Sciences
- Last refreshed: 30 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06231225.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing